ZYBT

Zhengye Biotechnology Holding Limited Ordinary Shares
ZYBT
Market cap $245M

6.34 USD

-0.95

13.03%

At close Jun 13, 4:00 PM EDT

After hours

6.41

+0.07

1.10%

1 day

-13.03%

5 days

3.59%

1 month

-14.44%

3 months

42.79%

6 months

30.45%

Year to date

30.45%

1 year

30.45%

5 years

30.45%

10 years

30.45%

About: Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs and is available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt.

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% more ownership

Funds ownership: 0% [Q4 2024] → 0% (+0%) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ZYBT.

See Analyst Rankings

Financial journalist opinion

Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

Jilin, China, May 23, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that it has received a letter from the NASDAQ Stock Market, dated May 20, 2025 (the “Delinquency Letter”), notifying the Company that it is not in compliance with the requirements for continued listing set forth in NASDAQ Listing Rule 5250(c)(1) because it did not timely file its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “2024 Annual Report”).

Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option

Jilin, China, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccine in China, today announced that the underwriter of its initial public offering (the "Offering") have exercised in full their option to purchase an additional 225,000 ordinary shares at a public offering price of $4.00 per ordinary share to cover over-allotments. Gross proceeds of the Company's initial public offering, including the exercise of the over-allotment, totaled $6.9 million, before deducting underwriting discounts and other related expenses. The ordinary shares began trading on the Nasdaq Capital Market on January 7, 2025 under the ticker symbol “ZYBT.”

Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option

U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline

Three very small Asian issuers and one blank check company listed in the US this past week, though the biggest headlines came from a sizable launch and notable new filings. Energy equipment and services provider Flowco launched the year's first major IPO, planning to raise $392 million and list in the week ahead. Two IPOs are currently scheduled in the week ahead, although some other small issuers may join the calendar throughout the week.

U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline

Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering

Jilin, China, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccine in China, today announced the closing of its initial public offering (the "Offering") of 1,500,000 ordinary shares at a public offering price of US$4.00 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and commenced trading on January 7, 2025 under the ticker symbol "ZYBT."

Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering

Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering

Jilin, China, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccine in China, today announced the pricing of its initial public offering (the "Offering") of 1,500,000 ordinary shares at a public offering price of US$4.00 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on January 7, 2025 under the ticker symbol "ZYBT." The Offering is expected to close on or about January 8, 2025, subject to the satisfaction of customary closing conditions.

Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering

Zhengye Biotechnology's Growth Slows As It Seeks U.S. IPO

Zhengye Biotechnology Holding Limited has filed for a $20 million IPO to raise capital for its acquisition program and new development capabilities. The company's revenue has declined, but it still maintains positive profits. The global animal vaccines market is expected to grow at a CAGR of 9.4% through 2030, presenting a significant opportunity for Zhengye.

Zhengye Biotechnology's Growth Slows As It Seeks U.S. IPO

See News Rankings

Charts implemented using Lightweight Charts™